47 related articles for article (PubMed ID: 24536060)
1. Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer.
de Bono JS; Piulats JM; Pandha HS; Petrylak DP; Saad F; Aparicio LM; Sandhu SK; Fong P; Gillessen S; Hudes GR; Wang T; Scranton J; Pollak MN
Clin Cancer Res; 2014 Apr; 20(7):1925-34. PubMed ID: 24536060
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.
Spreafico A; Chi KN; Sridhar SS; Smith DC; Carducci MA; Kavsak P; Wong TS; Wang L; Ivy SP; Mukherjee SD; Kollmannsberger CK; Sukhai MA; Takebe N; Kamel-Reid S; Siu LL; Hotte SJ
Invest New Drugs; 2014 Oct; 32(5):1005-16. PubMed ID: 24788563
[TBL] [Abstract][Full Text] [Related]
3. Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial.
Harrop R; Chu F; Gabrail N; Srinivas S; Blount D; Ferrari A
Cancer Immunol Immunother; 2013 Sep; 62(9):1511-20. PubMed ID: 23877659
[TBL] [Abstract][Full Text] [Related]
4. Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer.
Antonarakis ES; Heath EI; Smith DC; Rathkopf D; Blackford AL; Danila DC; King S; Frost A; Ajiboye AS; Zhao M; Mendonca J; Kachhap SK; Rudek MA; Carducci MA
Oncologist; 2013; 18(2):163-73. PubMed ID: 23340005
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209.
Eigl BJ; Chi K; Tu D; Hotte SJ; Winquist E; Booth CM; Canil C; Potvin K; Gregg R; North S; Zulfiqar M; Ellard S; Ruether JD; Le L; Kakumanu AS; Salim M; Allan AL; Feilotter H; Theis A; Seymour L
Oncotarget; 2018 Jan; 9(8):8155-8164. PubMed ID: 29487723
[TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.
James ND; Pirrie SJ; Pope AM; Barton D; Andronis L; Goranitis I; Collins S; Daunton A; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Hussain S; Russell M; Billingham LJ
JAMA Oncol; 2016 Apr; 2(4):493-9. PubMed ID: 26794729
[TBL] [Abstract][Full Text] [Related]
7. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.
Yu EY; Li H; Higano CS; Agarwal N; Pal SK; Alva A; Heath EI; Lam ET; Gupta S; Lilly MB; Inoue Y; Chi KN; Vogelzang NJ; Quinn DI; Cheng HH; Plymate SR; Hussain M; Tangen CM; Thompson IM
J Clin Oncol; 2015 May; 33(14):1601-8. PubMed ID: 25847934
[TBL] [Abstract][Full Text] [Related]
8. Enzalutamide in European and North American men participating in the AFFIRM trial.
Merseburger AS; Scher HI; Bellmunt J; Miller K; Mulders PF; Stenzl A; Sternberg CN; Fizazi K; Hirmand M; Franks B; Haas GP; de Bono J; de Wit R
BJU Int; 2015 Jan; 115(1):41-9. PubMed ID: 25123978
[TBL] [Abstract][Full Text] [Related]
9. Enzalutamide in metastatic prostate cancer before chemotherapy.
Beer TM; Armstrong AJ; Rathkopf DE; Loriot Y; Sternberg CN; Higano CS; Iversen P; Bhattacharya S; Carles J; Chowdhury S; Davis ID; de Bono JS; Evans CP; Fizazi K; Joshua AM; Kim CS; Kimura G; Mainwaring P; Mansbach H; Miller K; Noonberg SB; Perabo F; Phung D; Saad F; Scher HI; Taplin ME; Venner PM; Tombal B;
N Engl J Med; 2014 Jul; 371(5):424-33. PubMed ID: 24881730
[TBL] [Abstract][Full Text] [Related]
10. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer.
Langer CJ; Novello S; Park K; Krzakowski M; Karp DD; Mok T; Benner RJ; Scranton JR; Olszanski AJ; Jassem J
J Clin Oncol; 2014 Jul; 32(19):2059-66. PubMed ID: 24888810
[TBL] [Abstract][Full Text] [Related]
11. A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer.
Macaulay VM; Lord S; Hussain S; Maroto JP; Jones RH; Climent MÁ; Cook N; Lin CC; Wang SS; Bianchini D; Bailey M; Schlieker L; Bogenrieder T; de Bono J
Br J Cancer; 2023 Oct; 129(6):965-973. PubMed ID: 37537253
[TBL] [Abstract][Full Text] [Related]
12. Emerging Role of IGF-1 in Prostate Cancer: A Promising Biomarker and Therapeutic Target.
Liu G; Zhu M; Zhang M; Pan F
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831629
[TBL] [Abstract][Full Text] [Related]
13. Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer.
Davidson TM; Lebreton CL; Hendricksen AEW; Atkinson HJ; Larson MC; Oberg AL; Provencher DM; Glaspy JA; Karlan BY; Slamon DJ; Konecny GE; Ray-Coquard IL
Gynecol Oncol; 2023 Mar; 170():221-228. PubMed ID: 36709663
[TBL] [Abstract][Full Text] [Related]
14. Inflammation in Urological Malignancies: The Silent Killer.
Catalano M; Roviello G; Santi R; Villari D; Spatafora P; Galli IC; Sessa F; Conte FL; Mini E; Cai T; Nesi G
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614308
[TBL] [Abstract][Full Text] [Related]
15. Mini Review: Molecular Interpretation of the IGF/IGF-1R Axis in Cancer Treatment and Stem Cells-Based Therapy in Regenerative Medicine.
Lin SL; Lin CY; Lee W; Teng CF; Shyu WC; Jeng LB
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233084
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Evaluation of a New Format of
Liu Y; Yu S; Xu T; Bodenko V; Orlova A; Oroujeni M; Rinne SS; Tolmachev V; Vorobyeva A; Gräslund T
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890370
[TBL] [Abstract][Full Text] [Related]
17. Current Status of Monoclonal Antibodies-Based Therapies in Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis of Clinical Trials.
Tarrar TA; Anwar MY; Ali MA; Saeed M; Rehman S; Bajwa SF; Ayub T; Javid H; Ali R; Irshad A; Aiman W
Cureus; 2022 Mar; 14(3):e22942. PubMed ID: 35411277
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Janus Kinase 1 synergizes docetaxel sensitivity in prostate cancer cells.
Nalairndran G; Chung I; Abdul Razack AH; Chung FF; Hii LW; Lim WM; Looi CK; Mai CW; Leong CO
J Cell Mol Med; 2021 Sep; 25(17):8187-8200. PubMed ID: 34322995
[TBL] [Abstract][Full Text] [Related]
19. Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma.
Bolcaen J; Nair S; Driver CHS; Boshomane TMG; Ebenhan T; Vandevoorde C
Pharmaceuticals (Basel); 2021 Jun; 14(7):. PubMed ID: 34209513
[TBL] [Abstract][Full Text] [Related]
20. Cellular rewiring in lethal prostate cancer: the architect of drug resistance.
Carceles-Cordon M; Kelly WK; Gomella L; Knudsen KE; Rodriguez-Bravo V; Domingo-Domenech J
Nat Rev Urol; 2020 May; 17(5):292-307. PubMed ID: 32203305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
